Celltrion joins obesity drug race with oral, injectable pipeline

Celltrion aims to join the global race for obesity drugs with an oral pill and an injection for supporting weight loss, the Korean biopharmaceutical company said Tuesday. The biopharmaceutical company has been developing a quadruple-agonist injection under the pipeline name of CT-G32, a new first-in-class drug based on glucagon-like peptide-1, or GLP-1, which is widely used in existing weight-loss drugs such as Wegovy and Mounjaro. The Korean biosimilar maker said CT-G32 is designed to overcome

By The Korea Herald